All In Biotech

Drug Trial Radar · NCT06167681

The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

A Phase I/II Study to Assess the Safety, Tolerability and Efficacy of NouvNeu001 Injection for Mid- to Late-stage Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jan 17, 2024

Primary completion

Dec 2025

Study completion Jul 2029

Sponsor

Lead sponsor
iRegene Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.

Conditions

  • Parkinson Disease

Interventions

  • Human Dopaminergic Progenitor CellsBiological

    Single injection of Human Dopaminergic Progenitor Cells into the putamen/striatum region of brain.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 24 weeks and 48 weeks post-transplant
  2. Motor FunctionTime frame: 24 weeks post-transplant

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.